MX2016011333A - Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. - Google Patents

Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.

Info

Publication number
MX2016011333A
MX2016011333A MX2016011333A MX2016011333A MX2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A MX 2016011333 A MX2016011333 A MX 2016011333A
Authority
MX
Mexico
Prior art keywords
gemcitabine
bladder
treatment
methods
drug delivery
Prior art date
Application number
MX2016011333A
Other languages
English (en)
Inventor
Lee Heejin
Giesing Dennis
Daniel Karen
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2016011333A publication Critical patent/MX2016011333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Se proporcionan dispositivo de administración de fármacos y métodos para la administración de gemcitabina a un paciente que necesita el tratamiento mediante la administración de gemcitabina en la vejiga del paciente para lograr una concentración constante de gemcitabina en la orina en la vejiga para producir una concentración terapéuticamente eficaz de gemcitabina en los tejidos de la vejiga. En modalidades, la administración local a la vejiga del paciente es a una cantidad promedio de 1 mg/día a alrededor de 300 mg/día de gemcitabina (FBE).
MX2016011333A 2014-03-06 2015-03-06 Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. MX2016011333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
PCT/US2015/019262 WO2015134911A1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (1)

Publication Number Publication Date
MX2016011333A true MX2016011333A (es) 2016-12-07

Family

ID=52697553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011333A MX2016011333A (es) 2014-03-06 2015-03-06 Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.

Country Status (24)

Country Link
US (2) US20150250717A1 (es)
EP (2) EP3113782B1 (es)
JP (4) JP6901858B2 (es)
KR (1) KR102338079B1 (es)
CN (2) CN119950539A (es)
AU (4) AU2015226901B2 (es)
BR (1) BR112016020381A8 (es)
CA (1) CA2939979C (es)
DK (2) DK3113782T3 (es)
ES (2) ES3051417T3 (es)
FI (1) FI4124339T3 (es)
HR (2) HRP20251264T1 (es)
HU (1) HUE060704T2 (es)
IL (2) IL247347B2 (es)
LT (2) LT3113782T (es)
MX (1) MX2016011333A (es)
PL (2) PL3113782T3 (es)
PT (2) PT3113782T (es)
RS (2) RS63675B1 (es)
RU (1) RU2694902C1 (es)
SG (2) SG11201607342QA (es)
SI (1) SI4124339T1 (es)
SM (2) SMT202500385T1 (es)
WO (1) WO2015134911A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
LT3035991T (lt) 2013-08-19 2020-11-10 Taris Biomedical Llc Daugiablokiai vaistų vartojimo įtaisai
PT3113782T (pt) * 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina
SG10201913416PA (en) * 2016-05-06 2020-03-30 Taris Biomedical Llc Method of treating lower tract urothelial cancer
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
CN111787926A (zh) * 2017-11-08 2020-10-16 塔里斯生物医药公司 使用吉西他滨对膀胱癌进行治疗和维持疗法的方法
JP2021532155A (ja) 2018-08-01 2021-11-25 タリス バイオメディカル エルエルシー トロスピウムを使用した過活動膀胱の治療方法
JP7660066B2 (ja) * 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
JP2023512652A (ja) * 2020-01-27 2023-03-28 アイソラ セラピューティクス，インコーポレイテッド 管腔内局所薬剤送達のための組織内投与
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US7534241B2 (en) * 2002-09-23 2009-05-19 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
CA2649877A1 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
JP5560200B2 (ja) 2007-12-11 2014-07-23 マサチューセッツ インスチテュート オブ テクノロジー 膀胱および他の身体の小嚢又は管腔を治療するための埋め込み型薬物供給デバイス
CN102176931B (zh) 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
ES2401008T3 (es) 2009-06-26 2013-04-16 Taris Biomedical, Inc. Comprimidos farmacéuticos sólidos para dispositivos implantables para la administración de fármacos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
SI2512581T1 (sl) * 2009-12-17 2021-09-30 Taris Biomedical Llc Vsadljiva naprava z intravezikalno sprejemljivostjo
DK2525777T3 (da) * 2010-01-20 2019-07-01 Urogen Pharma Ltd Materiale og fremgangsmåde til at behandle interne hulrum
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
RU2598057C2 (ru) * 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
CA2882575C (en) * 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
SG11201507294WA (en) * 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
EP2968120B1 (en) 2013-03-15 2026-01-14 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
LT3035991T (lt) 2013-08-19 2020-11-10 Taris Biomedical Llc Daugiablokiai vaistų vartojimo įtaisai
CN105792880A (zh) * 2013-11-05 2016-07-20 塔里斯生物医药公司 渗透药物递送装置、套件以及方法
PT3113782T (pt) 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina

Also Published As

Publication number Publication date
JP7061595B2 (ja) 2022-04-28
HRP20221252T1 (hr) 2022-12-09
CN106102751A (zh) 2016-11-09
PT3113782T (pt) 2023-01-05
HRP20251264T1 (hr) 2025-12-05
RS67337B1 (sr) 2025-11-28
IL311410B2 (en) 2025-11-01
KR102338079B1 (ko) 2021-12-09
IL247347B2 (en) 2025-03-01
JP6901858B2 (ja) 2021-07-14
IL247347A0 (en) 2016-11-30
PL4124339T3 (pl) 2025-11-17
AU2015226901A1 (en) 2016-09-01
ES2930435T3 (es) 2022-12-13
AU2022215156B2 (en) 2024-09-05
US20150250717A1 (en) 2015-09-10
RU2694902C1 (ru) 2019-07-18
BR112016020381A8 (pt) 2018-05-02
NZ723303A (en) 2023-10-27
AU2024259822A1 (en) 2024-11-28
CN119950539A (zh) 2025-05-09
EP4124339B1 (en) 2025-09-10
JP7383681B2 (ja) 2023-11-20
LT3113782T (lt) 2022-11-25
PT4124339T (pt) 2025-11-04
SG11201607342QA (en) 2016-10-28
ES3051417T3 (en) 2025-12-29
RS63675B1 (sr) 2022-11-30
AU2022215156A1 (en) 2022-09-01
DK3113782T3 (da) 2022-10-17
JP2017508749A (ja) 2017-03-30
SG10202101978SA (en) 2021-04-29
SI4124339T1 (sl) 2025-11-28
EP3113782B1 (en) 2022-09-28
FI4124339T3 (fi) 2025-10-17
SMT202200449T1 (it) 2023-01-13
IL311410A (en) 2024-05-01
BR112016020381A2 (pt) 2017-08-15
IL311410B1 (en) 2025-07-01
JP2022022235A (ja) 2022-02-03
PL3113782T3 (pl) 2023-01-23
AU2020217383A1 (en) 2020-09-03
EP3113782A1 (en) 2017-01-11
SMT202500385T1 (it) 2025-11-10
AU2015226901B2 (en) 2020-05-14
CA2939979A1 (en) 2015-09-11
CA2939979C (en) 2023-03-21
JP2024009034A (ja) 2024-01-19
JP2019218410A (ja) 2019-12-26
US20220347091A1 (en) 2022-11-03
US20220117886A1 (en) 2022-04-21
HUE060704T2 (hu) 2023-04-28
EP4124339A1 (en) 2023-02-01
IL247347B1 (en) 2024-11-01
LT4124339T (lt) 2025-11-10
JP7802743B2 (ja) 2026-01-20
AU2020217383B2 (en) 2022-09-08
DK4124339T3 (da) 2025-10-13
WO2015134911A1 (en) 2015-09-11
KR20160124425A (ko) 2016-10-27

Similar Documents

Publication Publication Date Title
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2013155188A5 (es)
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
PH12021552977A1 (en) Methods of treating urinary system cancers
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
UA95104U (uk) Спосіб терапії хворих на негоспітальну пневмонію з супутньою хсн
UA82717U (ru) Способ лечения острого ишемического инсульта, обремененного ишемической болезнью сердца
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
UA109904C2 (uk) Комбінована терапія для шкірних розладів
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця
UA101725U (uk) Спосіб лікування хворих на рак прямої кишки